UNSPSC 51111630: Decitabine

This classification denotes a fbxw4 gene with the molecular formula C8H12N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 776B62CQ27, chemically known as 1,3,5-triazin-2(1h)-one, 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)- but generally known as decitabine, which bears US NIH Compound Identifier 16886. European Medicines Agency schedules Decitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06932MIG.

UNSPSC 51111630 Decitabine is a Commodity code that covers the procurement of this specific antineoplastic pharmaceutical product by state and local health agencies. State and local governments acquire decitabine primarily through health benefit programs, Medicaid agencies, and correctional or public health facilities to support cancer treatment for covered populations. The issuing bodies under this code are predominantly state health and human services departments managing pharmacy benefit programs, though the activity is not concentrated among a single agency type — Medicaid programs, state employee health plans, and public hospital systems each manage decitabine procurement within their respective benefit portfolios.

The Texas Health and Human Services Commission issued a Request for Information (RFI) in April 2026 (HHS0017013) to evaluate vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which would establish direct contracting pathways between the state's pharmacy benefit program and pharmaceutical manufacturers to optimize prescription fulfillment and cost management. While this RFI does not commit to specific procurement volumes or funding levels for decitabine itself, it signals Texas HHS's intent to develop alternative distribution and pricing models that could affect how state agencies source pharmaceutical products, including decitabine, outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI requests vendor experience with direct contracting for self-insured employers and health plans, capacity to negotiate based on net pricing models, and capability for value-based or outcomes-based agreements. Beyond this exploratory Texas initiative, the source provides no additional recent opportunities or geographic concentration data for decitabine procurement across other state or local jurisdictions.